Myelodysplastic syndrome can propagate from the multipotent progenitor compartment

Haematologica

Volumn 102, Issue 1, 2017, Pages e7-e10

  Rouault Pierre, Kevin ^a   Smith, Alexander E ^b,c   Mian, Syed A ^a,c   Pizzitola, Irene ^a   Kulasekararaj, Austin G ^b,c   Mufti, Ghulam J ^b,c   Bonnet, Dominique ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; CD45RA ANTIGEN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1;

ADULT; ANGPTLP5 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ASXL1 GENE; CASE REPORT; COLONY FORMING UNIT GM; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LETTER; MALE; MIDDLE AGED; MOUSE; MULTIPOTENT STEM CELL; MYELODYSPLASTIC SYNDROME; NONHUMAN; REFRACTORY ANEMIA; SKIN BRUISING; TRISOMY; WDR64 GENE; HEMATOPOIETIC STEM CELL; METABOLISM; PATHOLOGY; STEM CELL NICHE;

HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; STEM CELL NICHE;

EID: 85008420010     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.152520     Document Type: Letter

References (10)

1. Woll PS, Kjallquist U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25(6):794-808.
2. Mian SA, Rouault-Pierre K, Smith AE, et al. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat Commun. 2015;6:10004.
3. Jaiswal S, Ebert BL. MDS is a stem cell disorder after all. Cancer Cell. 2014;25(6):713-714.
4. Nilsson L, Astrand-Grundstrom I, Anderson K, et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002;100(1):259-267.
5. Medyouf H, Mossner M, Jann JC, et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014;14(6):824-837.
6. Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant stem cells. Blood. 2015;125(17):2630-2640.
7. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
8. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(4):365-375.
9. Macedo LC, Silvestre AP, Rodrigues C, et al. Genetics factors associated with myelodysplastic syndromes. Blood Cells Mol Dis. 2015;55(1):76-81.
10. Mossner M, Jann JC, Wittig J, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood. 2016;128(9):1246-1259.